Navigation Links
Blood-thinning copycat enters malaria fight
Date:6/1/2010

New treatments for malaria are possible after Walter and Eliza Hall Institute scientists found that molecules similar to the blood-thinning drug heparin can stop malaria from infecting red blood cells.

Malaria is an infection of red blood cells that is transmitted by mosquitoes. The most common form of malaria is caused by the parasite Plasmodium falciparum which burrows into red blood cells where it rapidly multiplies, leading to massive numbers of parasites in the blood stream that can cause severe disease and death.

At the moment, all anti-malarials licensed for use in humans block the development of the parasite within the red blood cell.

But Dr James Beeson, Ms Michelle Boyle and Dr Jack Richards from the institute's Infection and Immunity division, along with colleagues at the Burnet Institute and Imperial College London, have identified a new approach that could stop the parasite infecting red blood cells in the first place.

Using real-time video microscopy of red blood cell infection, the team showed that heparin-like carbohydrates blocked the ability of the malaria parasite to infect cells, Dr Beeson said.

"The malaria parasite needs a protein called MSP1 if it is to infect red blood cells as MSP1 is involved in the initial attachment of the parasite to the cells," Dr Beeson said.

"We have shown that heparin-like carbohydrates bind to MSP1 which stops the parasite from properly attaching to the red blood cell and, therefore, from invading."

The findings are published today in the international journal Blood and have raised the prospect of developing new anti-malarials that are based on the structure and activity of heparin-like molecules.

Although humans produce heparin-like molecules naturally, they do not occur at high enough levels in the blood to have anti-malarial activity, Dr Beeson said. "Heparin itself wouldn't be suitable as an anti-malarial as it prevents blood clotting. However, we have identified related compounds that are more potent against malaria than heparin but do not prevent blood clotting- these could form the basis of new antimalarial drugs."

Each year more than 400 million people contract malaria, and around one million people, mostly children, die from the disease.


'/>"/>

Contact: Penny Fannin
fannin@wehi.edu.au
61-417-125-700
Walter and Eliza Hall Institute
Source:Eurekalert  

Related biology news :

1. New blood-thinning drug safer than rat poison
2. NHGRI funds new Centers for Excellence in Ethical, Legal and Social Implications Research
3. DFG to establish 10 new collaborative research centers
4. US and UK research centers launch major collaboration on atmospheric research, technology
5. AMBER Alert Safety Centers to Provide Child Safety Precautions at the New Jersey State Fair at the Meadowlands
6. Weight Watchers vs. fitness centers
7. Zebra Technologies Enters Into Revolving Credit Agreement to Support Company Growth
8. NSF and EPA establish 2 centers for environmental implications of nanotechnology
9. Sicilian word enters British genetic language
10. From sheet metal elements to host cells: DFG launches 10 new collaborative research centers
11. Tellme Enters Automotive Market
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Blood-thinning copycat enters malaria fight
(Date:11/17/2016)... Market Watch: Primarily supported by ownership types; Private ... market is to witness a value of US$37.1 billion by ... Annual Growth Rate (CAGR) of 10.75% is foreseen from ... North America is not way behind ... at 9.56% respectively. Report Focus: The ...
(Date:11/15/2016)... , Nov 15, 2016 Research and ... Global Forecast to 2021" report to their offering. ... ... USD 16.18 Billion by 2021 from USD 6.21 Billion in 2016, ... Growth of the bioinformatics market is driven by the ...
(Date:6/22/2016)... BETHESDA, Md. , June 22, 2016  The American ... by Trade Show Executive Magazine as one of ... Summit on May 25-27 at the Bellagio in ... based on the highest percentage of growth in each of ... number of exhibiting companies and number of attendees. The 2015 ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016  HedgePath Pharmaceuticals, Inc. ... discovers, develops and plans to commercialize innovative therapeutics ... of common stock were approved for trading on ... trading on the OTCQX, effective today, under the ... the OTCQX market, companies must meet high financial ...
(Date:12/8/2016)... , Dec. 8, 2016  Partnering to fuel ... Ben Franklin Technology Partners of Southeastern Pennsylvania ... ("IHG"), the parent company of Independence Blue Cross; and ... announced their intentions for a $6 million funding initiative ... healthcare startups. Responding to a burgeoning economic ...
(Date:12/7/2016)... ... December 07, 2016 , ... A ... “in the setting of previously treated, advanced pancreatic cancer, liquid biopsies are not ... patient population and timing of blood sampling may improve the value of a ...
(Date:12/7/2016)... , Dec. 7, 2016 /PRNewswire/ - OncoQuest ... development and commercialization of immunotherapeutic products for the ... entered into an Antibody Manufacturing Development Program with ... , USA) for its oregovomab antibody product. Supported ... Phase IIb clinical study in ovarian cancer patients, ...
Breaking Biology Technology: